Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design

References

• HoganPDallTNikolovPEconomic costs of diabetes in the US in 2002Diabetes Care20032691793212610059
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSECruickshanksKJThe Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edemaOphthalmology19951027167831044
   PubMed Web of Science ®Google Scholar
• OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) GroupLancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• de SonnavilleJJSnoekFJCollyLPDevilléWWijkelDHeineRJWell-being and symptoms in relation to insulin therapy in type 2 diabetesDiabetes Care1998219199249614608
   PubMed Web of Science ®Google Scholar
• MartinezLConsoliSMMonnierLStudying the Hurdles of Insulin Prescription (SHIP©): development, scoring and initial validation of a new self-administered questionnaireHealth Qual Life Outcomes200755317727695
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRLauritzenTResistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) studyDiabetes Care2005282673267916249538
   PubMed Web of Science ®Google Scholar
• HorneRWeinmanJBarberNElliottRAMorganMConcordance, Adherence and Compliance in Medicine Taking: A conceptual map and research prioritiesLondon, UKNational Co-ordinating Centre for NHS Service Delivery and Organisation, NCCSDO2005
   Google Scholar
• CappelleriJCCefaluWTRosenstockJKouridesIAGerberRATreatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimenClin Ther20022455256412017400
   PubMed Web of Science ®Google Scholar
• FreemantleNBlondeLBolinderBReal-world trials to answer real-world questionsPharmacoeconomics20052374775416097837
   PubMed Web of Science ®Google Scholar
• FreemantleNStrackTRthe Real World TrialistsWill availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World TrialTrials200672516901335
   PubMed Web of Science ®Google Scholar
• Del PratoSBlondeLMartinezLEXPERIENCE Trial TeamThe effect of the availability of inhaled insulin on glycaemic control in patients with type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trialDiabet Med20082566267018435781
   PubMed Web of Science ®Google Scholar
• FreemantleNBlondeLDuhotDAvailability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetesDiabetes Care20052842742815677807
   PubMed Web of Science ®Google Scholar
• BradleyCThe Diabetes Treatment Satisfaction Questionnaire: DTSQBradleyCHandbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practiceChur, SwitzerlandHarwood Academic Publishers1994111132
   Google Scholar
• PlowrightRWitthausEBradleyCPsychometric evaluation of the Diabetes Treatment Satisfaction Questionnaire in 8 languagesProc Br Psychol Soc2000843
   Google Scholar
• The EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• BrooksREuroQol: the current state of playHealth Policy199637537210158943
   PubMed Web of Science ®Google Scholar
• StrackTRInhaled human insulinDrugs Today20064220722116703118
   PubMed Web of Science ®Google Scholar
• EdgertonDSCherringtonADNealDWInhalation of insulin (Exubera®) augments the efficiency of muscle glucose uptake in vivoDiabetes2006553604361017130510
   PubMed Web of Science ®Google Scholar
• EdgertonDSStettlerKMNealDWInhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogsJ Pharmacol Exp Ther20063191258126416963622
   PubMed Web of Science ®Google Scholar
• KingMNazarethILampeFImpact of participant and physician intervention preferences on randomized trials: a systematic reviewJAMA20052931089109915741531
   PubMed Web of Science ®Google Scholar
• Yki JarvinenHEskoNEeroHMarja RiittaTClinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failureAm J Med1988841851923044067
   PubMed Web of Science ®Google Scholar
• GroopLWidenETreatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?Diabetes Metab199117218223
   Web of Science ®Google Scholar
• CalvertMJMcManusRJFreemantleNManagement of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort studyBr J Gen Pract20075745546017550670
   PubMed Web of Science ®Google Scholar
• MackGSPfizer dumps ExuberaNature Biotechnol2007251331133218066009
   PubMed Web of Science ®Google Scholar
• GustafssonPTaylorAZanenPChrystynHCan patients use all dry powder inhalers equally well?Int J Clin Pract2005149Suppl1318
   Web of Science ®Google Scholar
• AhonenALeinonenMRanki-PesonenMPatient satisfaction with Easyhaler® compared with other inhalation systems in the treatment of asthmaCurr Ther Res Clin Exp2000616173
   Web of Science ®Google Scholar